Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature
- 14 May 2012
- journal article
- case report
- Published by Elsevier BV in Lung Cancer
- Vol. 77 (2), 464-468
- https://doi.org/10.1016/j.lungcan.2012.04.013
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Neoplastic Meningitis from Solid Tumors: New Diagnostic and Therapeutic ApproachesThe Oncologist, 2011
- Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?The Lancet Oncology, 2011
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)Journal of Clinical Oncology, 2011
- Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung DiseaseCase Reports in Oncology, 2011
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case reportJournal of Medical Case Reports, 2007
- Imaging of gefitinib-related interstitial lung disease: Multi-institutional analysis by the West Japan Thoracic Oncology GroupLung Cancer, 2006
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004